SpringerLink
Log in

Clinical Management of Oral Mucosal Disease: A Literature Review

  • Chapter
  • First Online:
Oral Mucosa in Health and Disease

  • 1420 Accesses

Abstract

Pathologies and symptoms that are seen in the oral mucosa may arise because of oral mucosal disease or from oral manifestations of systemic diseases. Many oral mucosal diseases exhibit an element of immune dysregulation and are frequently initiated by inflammatory processes that are either uncontrolled or unresolved.

The purpose of this chapter is to outline the types of regimes that are used to manage these diseases and to indicate treatment decision pathways where they are used in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 93.08
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 117.69
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 160.49
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Bijlsma JW, Jacobs JW. Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years. Ann N Y Acad Sci. 2014;18:27–31.

    Article  Google Scholar 

  2. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128(5):461–70.

    Article  PubMed  Google Scholar 

  3. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008;64(8):753–67.

    Article  PubMed  Google Scholar 

  4. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111(8):1133–45.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(1):s2–8.

    Article  PubMed  Google Scholar 

  6. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005;183(4):205–8.

    PubMed  Google Scholar 

  7. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2(6):817–33.

    Article  PubMed  Google Scholar 

  8. Nava F, Ghilotti F, Maggi L, Hatemi G, Del Bianco A, Merlo C, Filippini G, Tramacere I. Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behcet’s Syndrome. Cochrane Database Syst Rev. 2014;12(10):18.

    Google Scholar 

  9. Saleh Z, Arayssi T. Update on the therapy of Behcet disease. Ther Adv Chronic Dis. 2014;5(3):112–34.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jurge S, Kuffer R, Scully C, Porter SR. Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis. 2006;12(1):1–21.

    Article  PubMed  Google Scholar 

  11. Spivakovsky S. Inconclusive evidence on systemic treatments for recurrent aphthous stomatitis. Evid Based Dent. 2012;13(4):6400901.

    Google Scholar 

  12. Porter S, Scully C. Aphthous ulcers (recurrent). Clin Evid. 2005;13(94):1687–94.

    Google Scholar 

  13. Moots RJ, Fortune F, Situnayake D. The Behcet’s centres of excellence: a new paradigm for care delivery in complex diseases. Rheumatology (Oxford). 2017. https://doi.org/10.1093/rheumatology/kex037.

  14. Ambrose NL, Haskard DO. Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol. 2013;9(2):79–89.

    Article  PubMed  Google Scholar 

  15. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, Valente J. Behcet’s disease—a contemporary review. J Autoimmun. 2009;32(3–4):178–88.

    Article  PubMed  Google Scholar 

  16. Direskeneli H. Behcet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60(11):996–1002.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656–62.

    Article  PubMed  Google Scholar 

  18. Vitale A, Rigante D, Lopalco G, Emmi G, Bianco MT, Galeazzi M, Iannone F, Cantarini L. New therapeutic solutions for Behcet’s syndrome. Expert Opin Investig Drugs. 2016;25(7):827–40.

    Article  PubMed  Google Scholar 

  19. Mustafa MB, Porter SR, Smoller BR, Sitaru C. Oral mucosal manifestations of autoimmune skin diseases. Autoimmun Rev. 2015;14(10):930–51.

    Article  PubMed  Google Scholar 

  20. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis. 2005;11(6):338–49.

    Article  PubMed  Google Scholar 

  21. Wang H, Zhang D, Han Q, Zhao X, Zeng X, Xu Y, Sun Z, Chen Q. Role of distinct CD4(+) T helper subset in pathogenesis of oral lichen planus. J Oral Pathol Med. 2016;45:385–93.

    Article  PubMed  Google Scholar 

  22. Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10):e0164080.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ge Y, Xu Y, Sun W, Man Z, Zhu L, **a X, Zhao L, Zhao Y, Wang X. The molecular mechanisms of the effect of Dexamethasone and Cyclosporin A on TLR4/NF-kappaB signaling pathway activation in oral lichen planus. Gene. 2012;508(2):157–64.

    Article  PubMed  Google Scholar 

  24. Wang Y, Zhang H, Du G, Cao T, Luo Q, Chen J, Chen F, Tang G. Total glucosides of paeony (TGP) inhibits the production of inflammatory cytokines in oral lichen planus by suppressing the NF-kappaB signaling pathway. Int Immunopharmacol. 2016;36:67–72.

    Article  PubMed  Google Scholar 

  25. Al-Maweri SA, Kalakonda B, Al-Soneidar WA, Al-Shamiri HM, Alakhali MS, Alaizari N. Efficacy of low-level laser therapy in management of symptomatic oral lichen planus: a systematic review. Lasers Med Sci. 2017;24(10):017–2233.

    Google Scholar 

  26. Gupta S, Ghosh S. Interventions for the management of oral lichen planus: a review of the conventional and novel therapies. Oral Dis. 2017;5(10):12634.

    Google Scholar 

  27. Yacoub M-R, Berti A, Campochiaro C, Tombetti E, Ramirez GA, Nico A, Di Leo E, Fantini P, Sabbadini MG, Nettis E, Colombo G. Drug induced exfoliative dermatitis: state of the art. Clinical and Molecular Allergy: CMA. 2016;14(1):9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Farthing P, Bagan JV, Scully C. Mucosal disease series. Number IV. Erythema multiforme. Oral Dis. 2005;11(5):261–7.

    Article  PubMed  Google Scholar 

  29. Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KM, Wong GA, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194–227.

    Article  PubMed  Google Scholar 

  30. Black M, Mignogna MD, Scully C. Number II. Pemphigus vulgaris. Oral Dis. 2005;11(3):119–30.

    Article  PubMed  Google Scholar 

  31. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–8.

    Article  PubMed  Google Scholar 

  32. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, Amagai M. Pemphigus. Nat Rev Dis Primers. 2017;3(17026):26.

    Google Scholar 

  33. Ellebrecht CT, Payne AS. Setting the target for pemphigus vulgaris therapy. JCI Insight. 2017;2(5):92021.

    Article  Google Scholar 

  34. Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179–84.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Scully C, Lo Muzio L. Oral mucosal diseases: mucous membrane pemphigoid. Br J Oral Maxillofac Surg. 2008;46(5):358–66.

    Article  PubMed  Google Scholar 

  36. Schifter M, Yeoh SC, Coleman H, Georgiou A. Oral mucosal diseases: the inflammatory dermatoses. Aust Dent J. 2010;55(Suppl 1):23–38.

    Article  PubMed  Google Scholar 

  37. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360–4.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249–58.

    Article  PubMed  Google Scholar 

  39. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–4.

    Article  PubMed  Google Scholar 

  40. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H. Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960–8.

    Article  PubMed  Google Scholar 

  41. Pollard RP, Pijpe J, Bootsma H, Spijkervet FK, Kluin PM, Roodenburg JL, Kallenberg CG, Vissink A, van Imhoff GW. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren’s syndrome: a retrospective clinical study. J Rheumatol. 2011;38(10):2198–208.

    Article  PubMed  Google Scholar 

  42. Ferro F, Marcucci E, Orlandi M, Baldini C, Bartoloni-Bocci E. One year in review 2017: primary Sjogren’s syndrome. Clin Exp Rheumatol. 2017;35(2):179–91.

    PubMed  Google Scholar 

  43. Mavragani CP. Mechanisms and New Strategies for Primary Sjogren’s Syndrome. Annu Rev Med. 2017;68:331–43.

    Article  PubMed  Google Scholar 

  44. Zbar AP, Ben-Horin S, Beer-Gabel M, Eliakim R. Oral Crohn’s disease: is it a separable disease from orofacial granulomatosis? A review. J Crohns Colitis. 2012;6(2):135–42.

    Article  PubMed  Google Scholar 

  45. Yazisiz V. Similarities and differences between Behcet’s disease and Crohn’s disease. World J Gastrointest Pathophysiol. 2014;5(3):228–38.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Margaix-Muñoz M, Bagán JV, Jiménez Y, Sarrión MG, Poveda-Roda R. Graft-versus-host disease affecting oral cavity. A review. J Clin Exp Dent. 2015;7(1):e138–45.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Oral Immunology and Regenerative Medicine, Institute of Dentistry, Queen Mary School of Medicine and Dentistry, London, UK

    Lesley Ann Bergmeier & Farida Fortune

Authors
  1. Lesley Ann Bergmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farida Fortune
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley Ann Bergmeier .

Editor information

Editors and Affiliations

  1. Centre for Oral Immunobiology and Regenerative Medicine Institute of Dentistry, Queen Mary School of Medicine and Dentistry, London, United Kingdom

    Lesley Ann Bergmeier

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bergmeier, L.A., Fortune, F. (2018). Clinical Management of Oral Mucosal Disease: A Literature Review. In: Bergmeier, L. (eds) Oral Mucosa in Health and Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-56065-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56065-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56064-9

  • Online ISBN: 978-3-319-56065-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation